Medicina y salud
Disciplina temática
University of California, San Francisco
San Francisco, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California, San Francisco (67)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
Cancer, Vol. 130, Núm. 6, pp. 886-900
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411
-
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
Nature Genetics, Vol. 56, Núm. 1, pp. 27-36
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Blood Advances, Vol. 8, Núm. 1, pp. 194-206
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Cancer, Vol. 129, Núm. 13, pp. 2035-2046
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
-
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 12, pp. 811-818
2022
-
A dominant negative mutation uncovers cooperative control of caudal Wolffian duct development by Sprouty genes
Cellular and Molecular Life Sciences, Vol. 79, Núm. 10
-
A first update on mapping the human genetic architecture of COVID-19
Nature
-
Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)
Nature
-
Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study)
Microbiology Spectrum, Vol. 10, Núm. 3
-
Stroke genetics informs drug discovery and risk prediction across ancestries
Nature, Vol. 611, Núm. 7934, pp. 115-123
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
-
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer
Genome Medicine, Vol. 13, Núm. 1
-
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit
Schizophrenia Research, Vol. 227, pp. 10-17